The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin

Aaron L. Miller; Nicholas L. Rider; Richard B. Pyles; Barbara Judy; Xuping Xie; Pei-Yong Shi; Thomas G. Ksiazek

doi:10.1016/j.jaci.2022.03.026

The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin

Aaron L. Miller, Nicholas L. Rider, Richard B. Pyles, Barbara Judy, Xuping Xie, Pei-Yong Shi, Thomas G. Ksiazek

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1958-1959
Number of pages	2
Journal	Journal of Allergy and Clinical Immunology
Volume	149
Issue number	6
DOIs	https://doi.org/10.1016/j.jaci.2022.03.026
State	Published - Jun 2022

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2022.03.026

Cite this

@article{aa5c422372b442cf81383245f749db4a,

title = "The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin",

author = "Miller, {Aaron L.} and Rider, {Nicholas L.} and Pyles, {Richard B.} and Barbara Judy and Xuping Xie and Pei-Yong Shi and Ksiazek, {Thomas G.}",

note = "Funding Information: Supported by the National Institutes of Health (grants HHSN272201600013C , AI134907 , AI145617 , and UL1TR001439 [to P.-Y.S.]) and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gillson-Longenbaugh Foundation, and the Summerfield Roberts Foundation (to P.-Y.S.). ",

year = "2022",

month = jun,

doi = "10.1016/j.jaci.2022.03.026",

language = "English (US)",

volume = "149",

pages = "1958--1959",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "6",

}

TY - JOUR

T1 - The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin

AU - Miller, Aaron L.

AU - Rider, Nicholas L.

AU - Pyles, Richard B.

AU - Judy, Barbara

AU - Xie, Xuping

AU - Shi, Pei-Yong

AU - Ksiazek, Thomas G.

N1 - Funding Information: Supported by the National Institutes of Health (grants HHSN272201600013C , AI134907 , AI145617 , and UL1TR001439 [to P.-Y.S.]) and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gillson-Longenbaugh Foundation, and the Summerfield Roberts Foundation (to P.-Y.S.).

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85131701549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131701549&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2022.03.026

DO - 10.1016/j.jaci.2022.03.026

M3 - Letter

C2 - 35465974

AN - SCOPUS:85131701549

SN - 0091-6749

VL - 149

SP - 1958

EP - 1959

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 6

ER -

The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this